Cargando…

Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report

The treatment of metastatic melanoma changed dramatically with the discovery of immune checkpoint inhibitors (ICIs). Patients face prolonged exposure to these agents, which can frequently generate a large spectrum of adverse reactions. It has been shown that a considerable number of patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Oprea, Adela-Raluca, Benas, Arnaud, Havasi, Andrei, Gorzo, Alecsandra, Spinu, Stefan, Sur, Daniel, Burz, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329602/
https://www.ncbi.nlm.nih.gov/pubmed/35911362
http://dx.doi.org/10.7759/cureus.26359
_version_ 1784757952832339968
author Oprea, Adela-Raluca
Benas, Arnaud
Havasi, Andrei
Gorzo, Alecsandra
Spinu, Stefan
Sur, Daniel
Burz, Claudia
author_facet Oprea, Adela-Raluca
Benas, Arnaud
Havasi, Andrei
Gorzo, Alecsandra
Spinu, Stefan
Sur, Daniel
Burz, Claudia
author_sort Oprea, Adela-Raluca
collection PubMed
description The treatment of metastatic melanoma changed dramatically with the discovery of immune checkpoint inhibitors (ICIs). Patients face prolonged exposure to these agents, which can frequently generate a large spectrum of adverse reactions. It has been shown that a considerable number of patients treated with ICIs achieve a durable response to treatment that is maintained even after cessation. We present the case of a 75-year-old man with metastatic melanoma who underwent 95 cycles of nivolumab without significant treatment-related toxicities or progression. Future studies are needed to define more clearly the optimal duration of anti-programmed cell death protein 1 (PD-1) agents in patients with good tolerance and no progression. Patients could avoid discomfort caused by frequent physician visits, high additional costs, and possible adverse reactions that may occur after such a long period of exposure to immunotherapy.
format Online
Article
Text
id pubmed-9329602
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-93296022022-07-28 Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report Oprea, Adela-Raluca Benas, Arnaud Havasi, Andrei Gorzo, Alecsandra Spinu, Stefan Sur, Daniel Burz, Claudia Cureus Dermatology The treatment of metastatic melanoma changed dramatically with the discovery of immune checkpoint inhibitors (ICIs). Patients face prolonged exposure to these agents, which can frequently generate a large spectrum of adverse reactions. It has been shown that a considerable number of patients treated with ICIs achieve a durable response to treatment that is maintained even after cessation. We present the case of a 75-year-old man with metastatic melanoma who underwent 95 cycles of nivolumab without significant treatment-related toxicities or progression. Future studies are needed to define more clearly the optimal duration of anti-programmed cell death protein 1 (PD-1) agents in patients with good tolerance and no progression. Patients could avoid discomfort caused by frequent physician visits, high additional costs, and possible adverse reactions that may occur after such a long period of exposure to immunotherapy. Cureus 2022-06-27 /pmc/articles/PMC9329602/ /pubmed/35911362 http://dx.doi.org/10.7759/cureus.26359 Text en Copyright © 2022, Oprea et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Oprea, Adela-Raluca
Benas, Arnaud
Havasi, Andrei
Gorzo, Alecsandra
Spinu, Stefan
Sur, Daniel
Burz, Claudia
Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report
title Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report
title_full Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report
title_fullStr Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report
title_full_unstemmed Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report
title_short Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report
title_sort long term administration of nivolumab for metastatic melanoma: a case report
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329602/
https://www.ncbi.nlm.nih.gov/pubmed/35911362
http://dx.doi.org/10.7759/cureus.26359
work_keys_str_mv AT opreaadelaraluca longtermadministrationofnivolumabformetastaticmelanomaacasereport
AT benasarnaud longtermadministrationofnivolumabformetastaticmelanomaacasereport
AT havasiandrei longtermadministrationofnivolumabformetastaticmelanomaacasereport
AT gorzoalecsandra longtermadministrationofnivolumabformetastaticmelanomaacasereport
AT spinustefan longtermadministrationofnivolumabformetastaticmelanomaacasereport
AT surdaniel longtermadministrationofnivolumabformetastaticmelanomaacasereport
AT burzclaudia longtermadministrationofnivolumabformetastaticmelanomaacasereport